4/A: Olema Pharmaceuticals Director Amends Filing to Disclose Indirect Ownership of 1.8 Million Shares

Graham Walmsley, a director of Olema Pharmaceuticals, amends a previous SEC filing to include the indirect beneficial ownership of 1,800,000 shares held by Logos Global Master Fund LP.

Summary

• Graham Walmsley, a director of Olema Pharmaceuticals, filed an amendment to a previous Form 4.
• The amendment clarifies the indirect beneficial ownership of 1,800,000 shares of common stock held by Logos Global Master Fund LP.
• This holding was inadvertently omitted from the original Form 4 filed on December 17, 2024.
• Logos Master Fund did not participate in the transactions reported in the original Form 4.
• Walmsley disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

Sentiment

Score: 7

Explanation: The document is a routine regulatory filing correcting a previous omission. It doesn't indicate any positive or negative news about the company's performance, but the correction itself is a sign of diligence.

Industry Context

This filing is a routine disclosure related to insider ownership and is required by the SEC to ensure transparency in the market.

Stakeholder Impact

• The amendment provides greater transparency to shareholders regarding the beneficial ownership of Olema Pharmaceuticals' stock.

Key Dates

Keywords

Olema Pharmaceuticals, Graham Walmsley, Form 4, Beneficial Ownership, Logos Global Master Fund, Amendment, OLMA, Director